The effects of five years of growth hormone treatment on growth and body composition in patients with Temple syndrome

Autor: Alicia F. Juriaans, Demi J. Trueba-Timmermans, Gerthe F. Kerkhof, Lionne N. Grootjen, Sylvia Walet, Theo C.J. Sas, Joost Rotteveel, Nitash Zwaveling-Soonawala, Annemarie A. Verrijn Stuart, Anita C.S. Hokken-Koelega
Rok vydání: 2023
Předmět:
Zdroj: Hormone Research in Paediatrics.
ISSN: 1663-2826
1663-2818
DOI: 10.1159/000530420
Popis: Introduction: Temple syndrome (TS14) is a rare imprinting disorder caused by maternal uniparental disomy of chromosome 14 (UPD(14)mat), paternal deletion of 14q32.2 or an isolated methylation defect. Most patients with TS14 develop precocious puberty. Some patients with TS14 are treated with growth hormone (GH). However, evidence for the effectiveness of GH-treatment in patients with TS14 is limited. Methods: This study describes the effect of GH-treatment in 13 children and provides a subgroup analysis of 5 prepubertal children with TS14. We studied height, weight, body composition by Dual-Energy X-ray Absorptiometry (DXA), resting energy expenditure (REE) and laboratory parameters during 5 years of GH-treatment. Results: In the entire group mean (95% CI) height SDS increased significantly during 5 years of GH-treatment from -1.78 (-2.52; -1.04) to 0.11 (-0.66; 0.87). Fat mass percentage (FM%) SDS decreased significantly during the first year of GH, and lean body mass (LBM) SDS and LBM index increased significantly during 5 years of treatment. IGF-1 and IGF-BP3 levels rose rapidly during GH-treatment and the IGF-1/IGF-BP3 molar ratio remained relatively low. Thyroid hormone levels, fasting serum glucose and insulin levels remained normal. In the prepubertal group, median (IQR) height SDS, LBM SDS and LBM index also increased. REE was normal at start and did not change during one year of treatment. Five patients reached adult height and their median (IQR) height SDS was 0.67 (-1.83; -0.01). Conclusion: GH-treatment in patients with TS14 normalizes height SDS and improves body composition. There were no adverse effects or safety concerns during GH-treatment.
Databáze: OpenAIRE
Externí odkaz: